Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935867 | 0.85 | ALDH1A1 (0.57) | GBA1ALDH1A1LMNASIGMAR1HRH3 | |
| SCHEMBL3935123 | 0.85 | ALDH1A1 (0.57) | GBA1ALDH1A1LMNASIGMAR1HRH3 | |
| SCHEMBL188289 | 0.85 | ALDH1A1 (0.57) | GBA1ALDH1A1LMNASIGMAR1HRH3 | |
| SCHEMBL1955800 | 0.83 | ALDH1A1 (0.71) | GBA1ALDH1A1LMNA | |
| SCHEMBL2918814 | 0.82 | ALDH1A1 (0.53) | ALDH1A1FUCA1SIGMAR1HRH4HRH3 | |
| SCHEMBL3158673 | 0.81 | ALDH1A1 (0.61) | GBA1ALDH1A1LMNASIGMAR1HRH3 | |
| SCHEMBL17284215 | 0.80 | ALDH1A1 (0.55) | GBA1ALDH1A1LMNAFUCA1SIGMAR1 | |
| SCHEMBL2920097 | 0.80 | GBA1 (0.61) | GBA1ALDH1A1LMNAFUCA1HRH4 | |
| SCHEMBL2922811 | 0.80 | S1PR5 (0.50) | ALDH1A1FUCA1SIGMAR1S1PR5 | |
| SCHEMBL18587341 | 0.80 | FUCA1 (0.47) | GBA1ALDH1A1FUCA1SIGMAR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | GBA1 1698/4885ALDH1A1 3960/4885LMNA 4192/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | GBA1 826/4885ALDH1A1 1389/4885LMNA 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.